CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3

BACKGROUND: Platinum-based chemotherapy is emerging as the first line of treatment for castration resistant prostate cancer. Among the family of platinum (IV)-based compounds, a member known as CPA-7 inhibits the growth of multiple cancer cell lines. However, how and to what extent CPA-7 elicits its...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Meihua, Zhan, Fei, Zhao, Juan, Li, Qi, Wuyang, Jiazi, Mu, Guannan, Li, Dianjun, Zhang, Yanqiao, Huang, Xiaoyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4952363/
https://www.ncbi.nlm.nih.gov/pubmed/27435207
http://dx.doi.org/10.1186/s12885-016-2488-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4952363/
https://www.ncbi.nlm.nih.gov/pubmed/27435207
http://dx.doi.org/10.1186/s12885-016-2488-6

Ejemplares similares